Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy
NCT05071300Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Aug 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), sponsored by Ionis Pharmaceuticals. Primary endpoints: Change From Baseline in Platelet Count at 181 weeks, Number of Participants With Clinically Significant Changes From Baseline in Renal Function at 181 weeks and 12 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
eplontersen
03
Conditions
hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN)
Beyond the preview
Go deeper on NCT05071300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071300.